What are examples of combined hormonal contraceptives (CHC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Examples of Combined Hormonal Contraceptives (CHCs)

Combined hormonal contraceptives (CHCs) include combined oral contraceptives (COCs), the combined hormonal patch, and the combined vaginal ring. 1

Combined Oral Contraceptives (COCs)

  • COCs typically contain both estrogen (usually ethinyl estradiol) and a progestin component 1
  • Most currently available COCs contain ≤50 μg of ethinyl estradiol combined with a second, third, or fourth-generation progestin 1
  • Newer COCs may contain natural estrogens such as estradiol valerate (a prodrug of estradiol) or estetrol (a fetal estrogen) instead of synthetic ethinyl estradiol 1, 2

COC Formulations and Dosing Regimens

  • Monophasic dosing: same dose of hormones in each pill 1
  • Multiphasic dosing: varying weekly hormone doses to mimic the menstrual cycle 1
  • Cyclic formulations: active hormone pills for 21-24 days followed by placebo pills for 7-4 days 1
  • Extended cyclic formulations: active hormone pills for 84 days followed by placebo pills for 7 days 1
  • Continuous formulations: active hormone pills taken continuously 1

Examples of COCs by Progestin Generation

  • First-generation progestins: norethindrone 1, 3
  • Second-generation progestins: levonorgestrel 1, 3
  • Third-generation progestins: desogestrel, gestodene, norgestimate 1, 4
  • Fourth-generation progestins: drospirenone, dienogest 1, 5

Specific COC Example

  • Yaz: contains drospirenone (3 mg), a fourth-generation synthetic progestin, combined with ethinyl estradiol (0.02 mg) in a 24/4 day regimen 5, 6
  • Drospirenone possesses both antimineralocorticoid and antiandrogenic properties similar to natural progesterone 5

Combined Hormonal Patch

  • Transdermal contraceptive patch releases 150 μg of norelgestromin and 20 μg ethinyl estradiol daily 1
  • Provides comparable safety and pharmacokinetic profiles to COCs with similar hormone formulations 1

Combined Vaginal Ring

  • Vaginal contraceptive ring releases 120 μg etonogestrel and 15 μg ethinyl estradiol daily 1
  • Provides comparable safety and pharmacokinetic profiles to COCs with similar hormone formulations 1
  • May be preferred by some women, particularly those experiencing CHC-related female sexual dysfunction 7

Clinical Considerations

  • CHCs can be initiated at any time if it is reasonably certain that the woman is not pregnant 1
  • If CHCs are started >5 days since menstrual bleeding started, additional contraceptive protection is needed for the next 7 days 1, 8
  • Blood pressure measurement is recommended before initiation of CHCs 1, 8
  • CHCs do not protect against sexually transmitted infections (STIs) or human immunodeficiency virus (HIV) 1
  • Approximately 9 out of 100 women become pregnant in the first year of use with typical use of CHCs 1

Contraindications

  • History of deep vein thrombosis or pulmonary embolism 5, 4
  • Uncontrolled hypertension 5
  • Smoking in women over 35 years of age 5
  • History of breast cancer or other estrogen/progestin-sensitive cancers 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Choosing a combined oral contraceptive pill.

Australian prescriber, 2015

Guideline

Hormonal Composition and Clinical Implications of Yaz

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Perimenopausal combined hormonal contraception: focus on sexual function.

Climacteric : the journal of the International Menopause Society, 2025

Guideline

Combined Oral Contraceptives for Premenstrual Syndrome Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.